Anterior tibialis cmap amplitude correlations with impairment in CMT1A. Issue 4 (3rd March 2013)

• Record Type: Journal Article
• Authors: Komyathy, Kelsey; Neal, Stephanie; Feely, Shawna; Miller, Lindsey J.; Lewis, Richard A.; Trigge, George; Siskind, Carly E.; Shy, Michael E.; Ramchandren, Sindhu
• Is Part Of: Muscle & nerve. Volume 47:Issue 4(2013:Apr.)
• Page Start: 493
• Page End: 496
• Publication Date: 2013-03-03
• Subjects: Neuromuscular diseases -- Periodicals; Muscles -- Periodicals; Nerves -- Periodicals; 616.74
• DOI: 10.1002/mus.23614
• Languages: English
• ISSNs: 0148-639X

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <p> <italic>Introduction</italic>: CMT1A is the most common form of Charcot‐Marie‐Tooth disease (CMT), a slowly progressive neuropathy in which impairment is length dependent. Fibular nerve conduction studies to the anterior tibialis muscle (AT) may serve as a physiological marker of disease progression in patients with CMT1A. The objective of this study is to determine whether the AT compound muscle action potential (CMAP) amplitude correlates with impairment in patients with CMT1A. <italic>Methods</italic>: We correlated AT CMAP amplitudes and impairment measured by the CMT Neuropathy Score (CMTNS) in a cross‐section of 121 patients with CMT1A and a subset of 27 patients with longitudinal data. <italic>Results</italic>: AT CMAP amplitudes correlated with impairment as measured by the CMTNS in cross sectional analysis. Longitudinal changes in the AT CMAP showed a strong inverse correlation with leg strength but not other components of the CMTNS. <italic>Conclusions</italic>: AT CMAP amplitude may serve as a useful outcome measure for physiological changes in natural history studies and clinical trials for patients with CMT1A. Muscle Nerve, 2013</p> </abstract>